NeurOp develops medicine to treat central nervous system disorders such as major depression, neuropathic pain, ischemia (stroke) and Alzheimer’s.
Based on years of investigation by researchers at Emory and Duke, NeurOp’s drug compounds are based on blocking or activating aspects of the NMDA receptor, a critical signaling pathway in the central nervous system. Through this platform, the company has identified lead molecules that can act as antidepressants, analgesics and neuro-protective agents.
The total market for drugs that treat pain and depression is estimated to be at least $20 billion, while the global market for ischemia-related intervention is estimated at $15 billion or more per year.
Company website: NeurOp
Back to companies
Location: United States, Atlanta
Investors 2
| Date | Name | Website |
| - | Georgia Re... | gra.org |
| - | Ariel Sava... | asap-inves... |
Mentions in press and media 4
| Date | Title | Description | Source |
| 13.01.2016 | Five of Biotech Showcase’s most interesting startups | Interestingly, none of these startups are located in the usual geographical suspects: Boston, San Fr... | medcitynew... |
| 01.03.2013 | Early-stage drug firm Mnemosyne thinks the market is ripe fo... | So Mnemosyne has made that its job, screening hundreds of compounds with the goal of developing drug... | medcitynew... |
| - | Five of Biotech Showcase’s most interesting startups | Presenting at the J.P. Morgan Healthcare Conference may confer some level of credibility to a compan... | medcitynew... |
| - | Early-stage drug firm Mnemosyne thinks the market is ripe fo... | Mnemosyne Pharmaceuticals gets its offbeat name from the Greek goddess of memory. It’s fitting becau... | medcitynew... |